Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christos Mantzoros

Showing results (21-30 of 88) with videos related to

Pageof 9
Sort By:
Obesity (Silver Spring, Md.)|September 25, 2007
Relationship of plasma adiponectin with sex hormone and insulin-like growth factor levelsShelley S Tworoger, Christos Mantzoros, Susan E Hankinson
Metabolism: Clinical and Experimental|November 15, 2011
Resveratrol: is selectivity opening the key to therapeutic effects?Seung-Hwan Lee, Christos Mantzoros, Young-Bum Kim
Metabolism: Clinical and Experimental|December 18, 2013
Irisin in humans: recent advances and questions for future researchPontus A Boström, José Manuel Fernández-Real, Christos Mantzoros
Metabolism: Clinical and Experimental|August 12, 2018
Omics, big data and machine learning as tools to propel understanding of biological mechanisms and to discover novel diagnostics and therapeuticsNikolaos Perakakis, Alireza Yazdani, George E Karniadakis, et al.
The Medical Clinics of North America|November 21, 2017
Obesity as a DiseaseJagriti Upadhyay, Olivia Farr, Nikolaos Perakakis, et al.
Nutrition & Metabolism|June 30, 2005
Regulation of mouse hepatic genes in response to diet induced obesity, insulin resistance and fasting induced weight reductionR Michael Raab, John Bullen, Joanne Kelleher, et al.
Metabolism: Clinical and Experimental|June 21, 2011
trans-Fatty acids, insulin resistance/diabetes, and cardiovascular disease risk: should policy decisions be based on observational cohort studies, or should we be waiting for results from randomized placebo-controlled trials?Konstantinos N Aronis, Richard J Joseph, George L Blackburn, et al.
American Journal of Physiology. Endocrinology and Metabolism|January 5, 2012
Selective PPARγ modulator INT131 normalizes insulin signaling defects and improves bone mass in diet-induced obese miceDae Ho Lee, Hu Huang, Kangduk Choi, et al.
Bone|July 5, 2020
Delta-like 1 (DLK1) is a possible mediator of vitamin D effects on bone and energy metabolismAya Bassatne, Abbas Jafari, Moustapha Kassem, et al.
Diabetes Care|April 12, 2014
Can a selective PPARγ modulator improve glycemic control in patients with type 2 diabetes with fewer side effects compared with pioglitazone?Alex M DePaoli, Linda S Higgins, Robert R Henry, et al.
Pageof 9

Showing results (21-30 of 88) with videos related to

Sort By:
Pageof 9
Obesity (Silver Spring, Md.)|September 25, 2007
Relationship of plasma adiponectin with sex hormone and insulin-like growth factor levelsShelley S Tworoger, Christos Mantzoros, Susan E Hankinson
Metabolism: Clinical and Experimental|November 15, 2011
Resveratrol: is selectivity opening the key to therapeutic effects?Seung-Hwan Lee, Christos Mantzoros, Young-Bum Kim
Metabolism: Clinical and Experimental|December 18, 2013
Irisin in humans: recent advances and questions for future researchPontus A Boström, José Manuel Fernández-Real, Christos Mantzoros
Metabolism: Clinical and Experimental|August 12, 2018
Omics, big data and machine learning as tools to propel understanding of biological mechanisms and to discover novel diagnostics and therapeuticsNikolaos Perakakis, Alireza Yazdani, George E Karniadakis, et al.
The Medical Clinics of North America|November 21, 2017
Obesity as a DiseaseJagriti Upadhyay, Olivia Farr, Nikolaos Perakakis, et al.
Nutrition & Metabolism|June 30, 2005
Regulation of mouse hepatic genes in response to diet induced obesity, insulin resistance and fasting induced weight reductionR Michael Raab, John Bullen, Joanne Kelleher, et al.
Metabolism: Clinical and Experimental|June 21, 2011
trans-Fatty acids, insulin resistance/diabetes, and cardiovascular disease risk: should policy decisions be based on observational cohort studies, or should we be waiting for results from randomized placebo-controlled trials?Konstantinos N Aronis, Richard J Joseph, George L Blackburn, et al.
American Journal of Physiology. Endocrinology and Metabolism|January 5, 2012
Selective PPARγ modulator INT131 normalizes insulin signaling defects and improves bone mass in diet-induced obese miceDae Ho Lee, Hu Huang, Kangduk Choi, et al.
Bone|July 5, 2020
Delta-like 1 (DLK1) is a possible mediator of vitamin D effects on bone and energy metabolismAya Bassatne, Abbas Jafari, Moustapha Kassem, et al.
Diabetes Care|April 12, 2014
Can a selective PPARγ modulator improve glycemic control in patients with type 2 diabetes with fewer side effects compared with pioglitazone?Alex M DePaoli, Linda S Higgins, Robert R Henry, et al.
Pageof 9